|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
Xcellerex, Inc. Announces Sale of FlexFactory(TM) Bioproduction Line to Crucell N.V. (CRXL) for Vaccine, Monoclonal Antibody Manufacturing Facility
6/17/2009
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) is acquiring a FlexFactory™ bioproduction line and multiple XDR single-use bioreactors, to rapidly expand the capacity and flexibility of its manufacturing capabilities. Crucell is the latest company to purchase a FlexFactory, Xcellerex’s innovative, modular turnkey manufacturing platform. The project will deliver new, validated clinical manufacturing capacity at Crucell’s operations in Leiden, The Netherlands during the first quarter of 2010, enabling Crucell to commence production years faster than with conventional technologies. Financial terms were not disclosed.
|
|
|
|
|
|
|
|
|
|
|
|